Healthcare Sales & Marketing Network News: B-cell

Searching News Database: B-cell

HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Oct 2022
Cellecta, Inc. Launches DriverMap(TM) Adaptive Immune Receptor (AIR) TCR and BCR Kits for Comprehensive Immune Repertoire Profiling
Diagnostics Product Launch

HSMN NewsFeed - 8 Jul 2022
Sobi to license loncastuximab tesirine from ADC Therapeutics
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Mar 2022
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Feb 2021
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel

HSMN NewsFeed - 18 Nov 2020
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jun 2020
Enterome Completes �46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 15 Jun 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2020
HistoSonics Announces $40 Million Financing
Devices Venture Capital

HSMN NewsFeed - 21 May 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Mar 2020
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 5 Feb 2020
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Nov 2019
Aruvant Appoints William Chou as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 11 Oct 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jul 2019
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX(R) Platform Technology
Biopharmaceuticals Licensing

HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions

HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2019
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
Devices Venture Capital

HSMN NewsFeed - 21 Feb 2019
Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Na�ve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 13 Nov 2018
HOX Therapeutics Appoints Karl Keegan as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenstr�m's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Aug 2018
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 8 Aug 2018
Apexigen Raises $73 Million In Series B And Series C Financings
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenstr�m's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2018
Geoffrey B. Davis Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2018
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2017
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Na�ve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Apr 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Feb 2017
Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Mar 2016
ProNAi Therapeutics Appoints Jeffrey H. Cooper and Tran Nguyen to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Mar 2016
ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2016
LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Jan 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Dec 2015
ProNAi Therapeutics Appoints Dr. Keith Anderson and Dr. Gregg Smith to its Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Nov 2015
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jun 2015
Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Feb 2015
Genentech�s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin�s Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2014
Idera Announces Several Key Additions to Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead�s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 May 2014
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA�s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Dec 2013
Senesco Announces Letter of Intent to Merge with Fabrus
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 3 Jul 2013
FDA Grants Genentech�s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biopharmaceuticals Oncology Personalized Medicine

HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2012
CellTherapeutics� Pixuvri(R) Approved in EU as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons

HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 26 Jan 2012
Celgene to Acquire Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA

HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals� ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Aug 2010
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2010
GE Launches Study to Improve Diagnosis of Early Stage Colon Cancer
Diagnostics Oncology

HSMN NewsFeed - 16 Jun 2010
New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2010
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Jun 2010
Trubion Pharmaceuticals Wins Genentech and Biogen Idec Patent Appeal
Biopharmaceuticals Litigation

HSMN NewsFeed - 1 Jun 2010
Accentia Files Plan of Reorganization
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 21 Dec 2009
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Dec 2009
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 7 Oct 2009
Carl Zeiss Speeds Brain Mapping and 3-D Reconstruction with Advanced Electron Microscopy and Analysis Instruments
Devices Neurology

HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Jul 2009
CombinatoRx and Neuromed Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Personnel

HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2009
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Dec 2008
Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2008
Biolex Therapeutics Adds Two Drug Development Executives to Accelerate Development of Locteron(R) in Hepatitis C
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2008
Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron(R) Commercial Rights
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2008
Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron(R) in Hepatitis C
Biopharmaceuticasl Venture Capital

HSMN NewsFeed - 24 Sep 2008
ZaBeCor Pharmaceuticals Announces Formation of Biothorpe Pharmaceuticals
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2008
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals

HSMN NewsFeed - 27 May 2008
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals

HSMN NewsFeed - 28 Apr 2008
Nuon Therapeutics Inc. Completes $27 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2008
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Mar 2008
In Post-Vioxx Era, Biologics Are Reviving Arthritis Treatment Market
Biopharmaceuticals

HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Feb 2008
GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals

HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing

HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Nov 2007
Maxygen Updates Status of MAXY-alpha Program
Biopharmaceuticals

HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2007
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2007
Xencor Expands Series E Financing to $60 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Sep 2007
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2007
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology

HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2007
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2007
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2007
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2007
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Feb 2007
Protalex Appoints Edward W. Bernton, MD as Medical Director and Updates Development Plans for 2007
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2007
EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jan 2007
BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2007
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Results of Clinical Trial Program Suggest Fodosine(TM) Demonstrates Clinical Activity in Certain Types of Leukemia and Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2006
New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2006
BioCryst's Fodosine(TM) Granted Orphan Status In Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 9 Aug 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 7 Aug 2006
BioCryst Receives Special Protocol Assessment (SPA) From FDA for Pivotal Trial of Fodosine(TM) in T-Cell Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology

HSMN NewsFeed - 5 Jul 2006
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 20 Jun 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jun 2006
Favrille Announces FDA Allowance of Investigational New Drug Application for FAV-201, a Patient-Specific Immunotherapy for T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2006
Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2006
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Apr 2006
Epratuzumab for Immunotherapy of Lupus Results Published
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2006
Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Mar 2006
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Mar 2006
Schering-Plough Intensifies Focus On Europe, Latin America And Asia-Pacific
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Feb 2006
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2006
Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID (TM), a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Feb 2006
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin(R) in Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2006
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody 1D09C3 for Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Feb 2006
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jan 2006
Favrille Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of FavId for Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2006
Orphan Drug Designation Granted by European Commission for Anticancer Monoclonal Antibody 1D09C3 for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jan 2006
Baxter Receives Marketing Authorization From the European Commission for KIOVIG to Treat Immunodeficiencies
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Jan 2006
BioCryst Receives FDA Fast Track Designation for Peramivir
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Jan 2006
Favrille Receives FDA Fast Track Designation for FavId, Lead Product Candidate for Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 185

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 185 additional stories matching:
B-cell
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.